BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35925581)

  • 1. Association Between Prostate-Specific Antigen Screening and Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White US Veterans.
    Sherer MV; Qiao EM; Kotha NV; Qian AS; Rose BS
    JAMA Oncol; 2022 Oct; 8(10):1471-1476. PubMed ID: 35925581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
    Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
    JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.
    Burgess L; Aldrighetti CM; Ghosh A; Niemierko A; Chino F; Huynh MJ; Efstathiou JA; Kamran SC
    JAMA Netw Open; 2022 May; 5(5):e2211869. PubMed ID: 35576008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
    Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
    JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.
    Dess RT; Hartman HE; Mahal BA; Soni PD; Jackson WC; Cooperberg MR; Amling CL; Aronson WJ; Kane CJ; Terris MK; Zumsteg ZS; Butler S; Osborne JR; Morgan TM; Mehra R; Salami SS; Kishan AU; Wang C; Schaeffer EM; Roach M; Pisansky TM; Shipley WU; Freedland SJ; Sandler HM; Halabi S; Feng FY; Dignam JJ; Nguyen PL; Schipper MJ; Spratt DE
    JAMA Oncol; 2019 Jul; 5(7):975-983. PubMed ID: 31120534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating Prostate-Specific Antigen Screening for Young African American Men With Cancer.
    Qiao EM; Lynch JA; Lee KM; Kotha NV; Nalawade V; Voora RS; Qian AS; Nelson TJ; Yamoah K; Garraway IP; Stewart TF; Parsons JK; Rose BS
    J Natl Cancer Inst; 2022 Apr; 114(4):592-599. PubMed ID: 34893859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between prediagnostic prostate-specific antigen and prostate cancer probability in Black and non-Hispanic White men.
    Lee KM; Bryant AK; Lynch JA; Robison B; Alba PR; Agiri FY; Pridgen KM; DuVall SL; Yamoah K; Garraway IP; Rose BS
    Cancer; 2024 Jan; 130(2):224-231. PubMed ID: 37927109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.
    de Vos II; Remmers S; Hogenhout R; Roobol MJ;
    Eur Urol; 2024 Jan; 85(1):74-81. PubMed ID: 37919190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
    Mahal BA; Chen YW; Muralidhar V; Mahal AR; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Yu JB; Feng FY; Kim SP; Beard CJ; Martin NE; Trinh QD; Nguyen PL
    Ann Oncol; 2017 May; 28(5):1098-1104. PubMed ID: 28453693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities.
    Bryant AK; Lee KM; Alba PR; Murphy JD; Martinez ME; Natarajan L; Green MD; Dess RT; Anglin-Foote TR; Robison B; DuVall SL; Lynch JA; Rose BS
    JAMA Oncol; 2022 Dec; 8(12):1747-1755. PubMed ID: 36279204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis.
    Ma TM; Romero T; Nickols NG; Rettig MB; Garraway IP; Roach M; Michalski JM; Pisansky TM; Lee WR; Jones CU; Rosenthal SA; Wang C; Hartman H; Nguyen PL; Feng FY; Boutros PC; Saigal C; Chamie K; Jackson WC; Morgan TM; Mehra R; Salami SS; Vince R; Schaeffer EM; Mahal BA; Dess RT; Steinberg ML; Elashoff D; Sandler HM; Spratt DE; Kishan AU
    JAMA Netw Open; 2021 Dec; 4(12):e2139769. PubMed ID: 34964855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Veteran Status Mitigate Racial Disparities in Prostate Cancer Screening? Analysis of Prostate Specific Antigen Screening Patterns in the 2018 Behavioral Risk Factor Surveillance System Data.
    Alkhatib K; Labban M; Briggs L; Nguyen DD; Herzog P; Cole AP; Haag A; Trinh QD
    J Urol; 2022 May; 207(5):993-1000. PubMed ID: 34967663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations among statins, preventive care, and prostate cancer mortality.
    Kumar A; Riviere P; Luterstein E; Nalawade V; Vitzthum L; Sarkar RR; Bryant AK; Einck JP; Mundt AJ; Murphy JD; Rose BS
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):475-485. PubMed ID: 32029930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
    Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
    JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variations in Age-Adjusted Prostate Cancer Incidence Rates by Race and Ethnicity After Changes in Prostate-Specific Antigen Screening Recommendation.
    Lai SM; Keighley J; Garimella S; Enko M; Parker WP
    JAMA Netw Open; 2022 Nov; 5(11):e2240657. PubMed ID: 36342715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
    Hattangadi JA; Chen MH; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Black men with prostate cancer treated with radiation therapy in the Veterans Health Administration.
    McKay RR; Sarkar RR; Kumar A; Einck JP; Garraway IP; Lynch JA; Mundt AJ; Murphy JD; Stewart TF; Yamoah K; Rose BS
    Cancer; 2021 Feb; 127(3):403-411. PubMed ID: 33036065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?
    Hudson MA; Luo S; Chrusciel T; Yan Y; Grubb RL; Carson K; Scherrer JF
    Urol Oncol; 2014 Jan; 32(1):34.e9-18. PubMed ID: 23506962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-Value Prostate-Specific Antigen Screening in Older Males.
    Kalavacherla S; Riviere P; Javier-DesLoges J; Banegas MP; McKay RR; Murphy JD; Rose BS
    JAMA Netw Open; 2023 Apr; 6(4):e237504. PubMed ID: 37040113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer.
    Remmers S; Bangma CH; Godtman RA; Carlsson SV; Auvinen A; Tammela TLJ; Denis LJ; Nelen V; Villers A; Rebillard X; Kwiatkowski M; Recker F; Wyler S; Zappa M; Puliti D; Gorini G; Paez A; Lujan M; Nieboer D; Schröder FH; Roobol MJ
    Eur Urol; 2023 Nov; 84(5):503-509. PubMed ID: 37088597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.